- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03157401
Two Different Administration Methods of Tranexamic Acid on Perioperative Blood Loss During Total Hip Arthroplasty
Effects of Two Different Administration Methods of Tranexamic Acid on Perioperative Blood Loss During Total Hip Arthroplasty: a Prospective, Open-label, Randomized, Controlled Clinical Trial
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Background Total hip arthroplasty (THA) is extensively used in various hip diseases. Abundant blood supply at surgical area of bone tissue, intraoperative extensive cleaning, acetabular formation, femoral expansion, and medullary cavity and bone wound bleeding, will lead to extensive intraoperative and postoperative blood loss. The blood transfusion rate is high, which affects patients' rehabilitation. Previous studies have shown that 16%-69% patients required blood transfusion after first THA, which greatly affected patient's rehabilitation, and increased the risk of transfusion-related infection, hemolysis, immunosuppression, acute lung injury, and death. How to reduce perioperative blood loss in total hip arthroplasty has become a hot spot for joint surgeons.
Tranexamic acid as a synthetic antifibrinolytic drug is a synthetic analog of the amino acid lysine. Its mechanisms of action are the competitive inhibition of fibrinolytic zymogens, and noncompetitive inhibition of fibrinolytic enzymes. Tranexamic acid strongly inhibits plasmin-induced fibrin decomposition, reduces fibrinolytic system activity, to achieve local hemostasis and reduce bleeding (Appendix 1). However, the route of administration of tranexamic acid is diverse, and the best way to administer is not clear. A large number of studies have confirmed that during total knee arthroplasty and THA, intravenous application of tranexamic acid can significantly reduce postoperative blood loss, blood transfusion volume and blood transfusion rate. Intra-articular application of tranexamic acid can reduce the drainage volume of drainage tube, total blood loss, blood transfusion volume and blood transfusion rate after joint arthroplasty. Moreover, hemoglobin levels remarkably increase after surgery. More and more studies and meta-analysis have verified that tranexamic acid has a "target effect". Reasonable use of tranexamic acid does not increase the risk of deep venous thrombosis or pulmonary embolism after hip and knee arthroplasties. Simultaneously, tranexamic acid has a good potency ratio.
Adverse events
- To record adverse events during follow up, including incision pain, infection, hip pain, peripheral nerve injury, pulmonary embolism, lower extremity hematoma, deep vein thrombosis, and fixator falling off.
- If severe adverse events occur, investigators would report details, including the date of occurrence and measures taken to treat the adverse events, to the principle investigator and the institutional review board within 24 hours.
Data collection, management, analysis, open access
- Data collection: Case report forms were collected and processed using Epidata software (Epidata Association, Odense, Denmark). These data would be recorded electronically.
- Data management: Tengzhou Central People's Hospital, China would preserve all of the data regarding this trial. Only the project manager has the right to query the database file. This arrangement will not be altered.
- Data analysis: A professional statistician would statistically analyze the electronic database and create an outcome analysis report. An independent data monitoring committee would supervise and manage the trial data.
- Data open access: Anonymized trial data will be published at www.figshare.com.
Statistical analysis
- Statistical analysis would be performed using SPSS 19.0 software (IBM, Armonk, NY, USA) and would follow the intention-to-treat principle.
- Normally distributed measurement data would be expressed as means ± standard deviation and minimums and maximums. Non-normally distributed measurement data would be expressed as the lower quartile (q1) and median and upper quartiles (q3). Count data would be expressed as a percentage.
- The differences in hidden blood loss, dominant blood loss and mean blood loss in each group at intraoperative, postoperative 1 and 3 days would be compared using two-factor analysis of variance with repeated measures. Paired comparison of intergroup data would be conducted using least significant difference. Blood transfusion rate and incidence of adverse reactions in each group were compared using Pearson X2 test.
- The significance level would be α = 0.05.
Studietype
Inschrijving (Verwacht)
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Femoral head necrosis or femoral neck fracture patients undergoing the first unilateral THA
- Bilateral hips with indications for THA in patients with femoral head necrosis, but after arthroplasty on one side, the arthroplasty on the other side will be conducted when choosing a good time and physical condition allows.
- Average age: 62.52 years
- Sex ratio of males to females: 11:19
- Signed informed consent
Exclusion Criteria:
- Coagulation disorders and anemia
- History of infection on the affected extremity
- History of vascular embolization and long-term oral anticoagulant drugs
- Contraindications for tranexamic acid or anticoagulant drugs
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
---|---|
intravenous infusion group
In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery.
After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
|
In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery.
After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
Andere namen:
|
intra-articular injection group
In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery.
After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
|
In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery.
After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
Andere namen:
|
control group
In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery.
After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
|
In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery.
After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
hidden blood loss
Tijdsspanne: at postoperative 1 and 3 days
|
Hidden blood loss was calculated by the circulation volume proposed by Gross, i.e., total erythrocyte loss is equal to preoperative total blood volume × (hematocrit preoperatively - hematocrit postoperatively 3 days).
|
at postoperative 1 and 3 days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Dominant blood loss
Tijdsspanne: at intraoperative, postoperative 1 and 3 days
|
Dominant blood loss includes intraoperative blood loss and postoperative blood loss.
Intraoperative blood loss was quantified by measuring irrigation fluid and weight measurement of surgical sponges.
Postoperative blood loss was quantified by measuring wound drainage volume and weight measurement of surgical sponges.
|
at intraoperative, postoperative 1 and 3 days
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Zhenyang Hou, Master, Tengzhou Central People's Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- TengzhouCPH_01
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Totale heupartroplastiek
-
Smith & Nephew, Inc.Nor Consult, LLCVoltooidJourney II XR Total Knee-systeemVerenigde Staten
-
Smith & Nephew, Inc.VoltooidJourney II BCS Total Knee-systeemVerenigde Staten, België, Nieuw-Zeeland
-
Smith & Nephew, Inc.Nor ConsultVoltooidJourney II CR Total Knee-systeemVerenigde Staten
-
Istituto Ortopedico RizzoliWervingHip Impingement Syndroom | Prothetische complicatieItalië
-
University of PittsburghAanmelden op uitnodigingAcetabulaire labrale scheur | Hip Impingement SyndroomVerenigde Staten
-
Ottawa Hospital Research InstituteVoltooidFemoroacetabulaire Hip Impingement SyndroomCanada
-
Bezirkskrankenhaus St. Johann in TirolVoltooidHeup ziekte | Hip Impingement Syndroom | Femoro-acetabulaire impingementOostenrijk
-
Northwestern UniversityIngetrokkenHeuppijn chronisch | Bloedverlies | Heup verwondingen | Femoro acetabulaire impingement | Hip Impingement SyndroomVerenigde Staten
-
Steadman Philippon Research InstituteUnited States Department of Defense; Office of Naval Research (ONR)BeëindigdFibrose | Heup artrose | Kraakbeen schade | Hip Impingement SyndroomVerenigde Staten
Klinische onderzoeken op intravenous infusion group
-
Radha GopalanAmerican Regent, Inc.Aanmelden op uitnodigingHartfalen | IjzertekortVerenigde Staten
-
Nova Scotia Health AuthorityVoltooid
-
Chinese University of Hong KongActief, niet wervendIntellectuele handicap, MildHongkong
-
Karadeniz Technical UniversityVoltooidHemodialyse | Eenzaamheid | Geluk | Aanpassing | Dierondersteunde therapie | SymptoomKalkoen
-
University of LisbonAssociacao Protectora dos Diabeticos de PortugalVoltooid
-
University of MichiganVoltooid
-
University of TennesseeNational Cancer Institute (NCI); Regional One HealthWervingGewichtsverlies | Overgewicht en obesitas | Gedrag, gezondheidVerenigde Staten
-
The Policy & Research GroupMathematica Policy Research, Inc.; The Office of Adolescent Health, HHSVoltooid
-
Cukurova UniversityVoltooidZwangerschap, hoog risico | Angst staat | SlaapkwaliteitKalkoen
-
Loma Linda UniversityBaxter Healthcare CorporationVoltooidBloeding | Aangeboren hartfout | Chirurgie-geïnduceerde weefselverklevingenVerenigde Staten